Vodafone Group and Piramal Healthcare today announced that the latter has agreed to purchase approximately 5.5% of the issued equity share capital of Vodafone India Limited (VIL) from Essar for a cash consideration of approximately Rs 3007 crore (£385 million), taking Piramal’s total shareholding in Vodafone India to 11%.

The transaction follows the settlement between Vodafone and Essar over the sale of Essar’s approximately 33% stake in VIL, announced in July 2011, and the purchase by Piramal of approximately 5.5% of the issued share capital of VIL from Essar in August 2011. This completes the exit of the Essar group as a shareholder in VIL.

Also Read   Related Stories News Now - Vodafone, Airtel woo users from axed players - Trai favours auction of 2G spectrum in phases - SC ruling to trigger telecom industry shakeout - Crisil reaffirms ratings on Idea, Tata Tele - Top telcos to gain ground, upstarts to feel the pinch - Delay in phone bill payments may hurt credit scores

Also Read   Related Stories News Now - Markets post worst May performace since 2006 - Add value to precious material before export: Assocham - Asian gold up, but set for worst May performance in 30 years - Spicejet to be first carrier to import jet fuel directly - Bandh affects normal life in Jammu & adjoining areas More

Vodafone last year bought 22% from the Essar Group and Piramal bought 5.5%. The world's biggest cellular carrier by revenue, Vodafone is the largest overseas corporate investor in India. Vodafone, which entered India in 2007 when it bought control of Hong Kong-based Hutchison Whampoa Ltd's India phone business, is the second-largest player by revenue market share behind Bharti Airtel.

Vodafone has said it plans to take its India unit public but has not set a timeframe.

The Vodafone stake buy is the cash-flush drugmaker's second unrelated investment after it bought PE firms IndiaReit Fund Advisors and IndiaReit Investment Managers.

The company, which last year bought about 5.5% in Vodafone from Essar, was sitting on a cash pile of Rs 10,000 crore, it said last August.

Piramal sold its Indian formulations business to US-based Abbott Laboratories in 2010.

It has been looking for investments outside the pharmaceutical sector and had recently announced a foray into the financial services segment. 

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets post worst May performace since 2006 - Add value to precious material before export: Assocham - Asian gold up, but set for worst May performance in 30 years - Spicejet to be first carrier to import jet fuel directly - Bandh affects normal life in Jammu & adjoining areas

Tags : Piramal Healthcare | Vodafone | Essar   Read Business news in  Advertisements -  India's no. 1 Property Site. Click here to know more -  "Discover The Power of One" -  Help a Child Achieve her. Click to know more -  The Best Seller is Also the No. 1 in Mileage. Click here -  Watch The Film Here. Click here to know more.. -  Learn How One City is Running on FOOD SCRAPS. -  1 billion in saving for Unilever without any tangles. -  A Brand New Server at a Price That Fits Your Budget. Click here -  One Partnership Endless Possibilities. Click here to know more -  Helping doctors detect diseases earlier, saving costs & extending lives. -  Which is the best plan for your daughter -  Check out the TRUE COLOURS of your Stocks, Now for FREE! -  One of the leading business schools in the world.Know More -  2 Lac Apartments, 1 Lac House / Plots. Click here